Lipoprotein classes and coronary disease regression

Current Opinion in Lipidology

Volumn 9, Issue 4, 1998, Pages 329-336

  Zambon, Alberto ^a,b   Hokanson, John E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID COMPOSITION; LIPID METABOLISM; PRIORITY JOURNAL; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; LIPOPROTEINS; TRIGLYCERIDES;

EID: 0031664263     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199808000-00008     Document Type: Article

References (52)

1. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM Jr. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997; 8:354-361. This is a thorough and complete review of the recent trials with lipid lowering therapy and the effect on coronary and carotid disease severity, with a particular focus on subjects with CAD and mild to moderate hyperlipidemia.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study. Group N Engl J Med 1995; 333:1301-1307.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels Results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-1622. A total of 6605 individuals (5608 men and 997 women) free of any evidence of cardiovascular disease and with total cholesterol between 180 and 264 mg/dl. LDL-C between 130 and 190mg/dl, HDL-C · 45mg/dl for men and · 47mg/dl for women, and triglyceride · 400mg/dl were randomized to receive lovastatin (20 mg/day or 40 mg/day if LDL-C remained · 110 mg/dl) or placebo and were follow for an average of 5.2 years. Lovastatin therapy decreased total cholesterol by 18% and LDL-C by 25%, triglyceride by 15%, and increased HDL-C by 6%. There were fewer primary end point events (acute myocardial infarction, unstable angina or sudden cardiac death) in the group receiving lovastatin therapy compared with the placebo group (relative risk 0.63, 95% confidence intervals 0.50-0.79, P · 0.001). This study demonstrates that treatment with lovastatin 'can reduce the risk for first acute major coronary disease events in men and women with average or mildly elevated total cholesterol and LDL-C levels and below-average HDL-C levels'.
4. The 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
6. West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, et al. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials 1996; 17:550-583.
7. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study. Circulation 1998; 97:1440-1445. In individuals with hypercholesterolemia without documented CAD, a fall of the LDL levels in the range of 24% is sufficient to produce full benefit in patients taking 40 mg/day of pravastatin; further decrease in LDL was not associated with larger reduction in CAD risk. Comparison of the pravastatin and placebo groups with the same in-trial LDL levels, demonstrated that patients receiving pravastatin had lower CAD risk that those receiving placebo LDL reduction alone does not seem to explain entirely the CAD benefits observed with pravastatin.
8. Sacks FM, Moye LA, Davis BR, Cole TG, Rouileau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trail. Circulation 1998; 97:1446-1452. In post-myocardial infarction patients with average cholesterol levels, a similar relative risk was observed with pravastatin, whether LDL was reduced by 20-25% or by as much as 40%. Pravastatin individuals had 24% fewer events than placebo individuals with similar LDL values. Statistical analyses performed demonstrated that 33% of the total pravastatin effect was not attributable to changes in LDL levels and that trigylceride levels during follow-up were a significant predictor of coronary events.
9. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849-853.
10. Schaefer S, Hussein H, Gershony GR, Rutledge JC, Kappagoda CT. Regression of severe atherosclerotic plaque in patients with mild elevation of LDL cholesterol. J Invest Med 1997; 45:536-541.
11. Tamura A, Mikuriya Y, Nasu M. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group. Am J Cardiol 1997; 79:893-896.
12. Bestehorn HP, Rensing UFE, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. Eur Heart J 1997; 18:226-234.
13. Sutherland WH, Restieaux NJ, Nye ER, Williams MJ, de Jong SA, Robertson MC, Walker HL. IDL composition and angiographically determined progression of athersclerotic lesions during simvastatin therapy. Arterioscler Thromb Vasc Biol 1998; 18:577-583.
14. Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93:1826-1835.
15. Herd JA, Ballantyne CM, Farmer JA, Ferguson J Jr, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations [Lipoprotein and Coronary Atherosclerosis Study (LCAS)]. Am J Cardiol 1997; 80:278-286.
16. Park JW, Merz M, Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis. J Heart Lung Transplant 1997; 16:290-297.
17. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997; 96:2137-2143.
18. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022-2026.
19. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obslructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial. N Engl J Med 1997; 336:153-162. Aggressive reduction of LDL cholesterol < 100 mg/dl with lovastatin reduced the progression of atherosclerosis in grafts compared with a milder LDL reduction (almost 130 mg/dl).
20. Cobbaert C, Jukema JW, Zwinderman AH, Withagen AJ, Lindemans J, Bruschke AV. Modulation of lipoprotein (a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol Regression Growth Evaluation Stalin Study (REGRESS) Study Group. J Am Coll Cardiol 1997; 30:1491-1499. Serum Lp(a) levels are week predictors of angiographic changes in normocholesterolemic or moderately hypercholesterolemic individuals. Atherogenicy is modulated by HDL levels and is markedly higher in the presence of low HDL-C.
21. Brown BG, Fuster V. Impact of management in stabilization of coronary disease. In: Fuster V, Ross R, Topol EJ (editors). Atherosclerosis and coronary disease. Lippincott-Raven: Philadelphia; 1996, pp. 191-205.
22. Aengevaeren WR, Uijen GJ, Jukema JW, Bruschke AV, van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the Regression Growth Evaluation Statin Study (REGRESS). Circulation 1997; 96:429-435. Treatment with pravastatin over 2 years, resulted in a preserved myocardial perfusion which represents a combined measure of functional and structural changes of the coronary circulation.
23. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, Selwyn AP. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease [see comments]. Circulation 1997; 95:324-328. Lipid-lowering treatment with lovastatin reduced myocardial ischemia (ECG episodes of ST-segment depression) in the short term An important clinical observation of the effect of treatment, lipid and non-lipid mediated, on the arterial wall vasoactivity, which appears to precede in time regression of atheroma.
24. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:100-107.
25. Scanu AM. Structural and functional polymorphism of lipoprotein (a): biological and clinical implications. Clin Chem 1995; 41:170-172.
26. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997; 17:239-245. One hundred and 34 matched case-control pairs (90 men and 44 women) from the Stanford Five-City Project had Lp(a) levels measured. Median Lp(a) level were 41.8 versus 21.2 nmol/l (P < 0.01) in men versus control individuals, and 32.5 versus 21.2 nmol/l (non-significant) in women versus control individuals. This study provides evidence that Lp(a) levels predict coronary artery disease in men. The association between Lp(a) levels and coronary disease in women may not be as strong as in men.
27. Marburger C, Hambrecht R, Niebauer J, Schoeppenthau M, Scheffler E, Hauer K, et al. Association between lipoprotein (a) and progression of coronary artery disease in middle-aged men. Am J Cardiol 1994; 73:742-746.
28. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a) [see comments]. Circulation 1995; 91:948-950.
29. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-2540.
30. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274:1771-1774.
31. Skinner JS, Farrer M, Albers CJ, Piper K, Neil HA, Adams PC. Serum Lp (a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery Heart 1997; 78:131-135.
32. Kronenberg F, Trenkwalder E, Strum W, Katherin H, Konig P, Neyer U, et al. LDL-unbound apolipoprotein (a) and carotid atherosclerosis in hemodialysis patients. Clin Genetics 1997; 52:377-386.
33. Baldassarre D, Tremoli E, Franceschini G, Michelagnoli S, Sirtori CR. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients Stroke 1996; 27:1044-1049.
34. Gofman JW, DeLalla O, Flazier F, Freeman NK, Lindgren FT, Nichols AV, et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary disease. Plasma 1954; 2:413-483.
35. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975; 1:16-19.
36. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease The Framingham Study. Am J Med 1977; 62:707-714.
37. Austin MA, King M-C, Vranizan K, Krauss RM. The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506.
38. Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascul Risk 1996; 3:213-219.
39. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875-881.
40. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts Lipid and nonlipid factors. Circulation 1990; 81:470-476.
41. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis 1996; 122:105-115.
42. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Research Group. Ann Intern Med 1993; 119:969-976.
43. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90:42-49.
44. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16:697-704.
45. Tkac I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997; 17:3633-3638.
46. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, et al. Beneficial etfects of colestipol-niacin therapy on the common carotid artery Two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993; 88:20-28.
47. Crouse J, Parks J, Schey H, Kahl F. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985; 26:566-574.
48. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 1988; 260:1917-1921.
49. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996; 94:2146-2153.
50. Zambon A, Brown BG, Hokanson JE, Brunzell JB. Hepatic lipase changes predict coronary artery disease progression/regression in the familial athersoclerosis treatment study (FATS). Circulation 1996; 94 (Suppl. 1):539.
51. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998 (in press).
52. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93. In men with CAD. the TaqIB polymorphism of the CETP gene is associated with coronary lesion progression. This marker appears to predict angiographic response to pravastatin. These findings may be clinically relevant because of the high frequency of this polymorphism (16% were carriers of the genotype that is associated with poor response to therapy).